Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jun;41(6):603-613.
doi: 10.1007/s40264-017-0635-x.

Evidence-Based Recommendations to Improve the Safe Use of Drugs in Patients with Liver Cirrhosis

Rianne A Weersink  1   2 , Margriet Bouma  3 , David M Burger  4 , Joost P H Drenth  5 , S Froukje Harkes-Idzinga  6 , Nicole G M Hunfeld  7 , Herold J Metselaar  8 , Margje H Monster-Simons  9   10 , Katja Taxis  11 , Sander D Borgsteede  12   13
Affiliations
Review

Evidence-Based Recommendations to Improve the Safe Use of Drugs in Patients with Liver Cirrhosis

Rianne A Weersink et al. Drug Saf. 2018 Jun.

Abstract

Introduction: The presence of liver cirrhosis can have a major impact on pharmacodynamics and pharmacokinetics, but guidance for prescribing is lacking.

Objective: The aim of this study is to provide an overview of evidence-based recommendations developed for the safe use of drugs in liver cirrhosis.

Methods: Recommendations were based on a systematic literature search combined with expert opinion from a panel of 10 experts. The safety of each drug was classified as safe, no additional risks known, additional risks known, unsafe, unknown or the safety class was dependent on the severity of liver cirrhosis (Child-Pugh classification). If applicable, drug-specific dosing advice was provided. All recommendations were implemented in clinical decision support systems and on a website.

Results: We formulated 218 recommendations for a total of 209 drugs. For nine drugs, two recommendations were formulated for different administration routes or indications. Drugs were classified as 'safe' in 29 recommendations (13.3%), 'no additional risks known' in 60 (27.5%), 'additional risks known' in 3 (1.4%), and 'unsafe' in 30 (13.8%). In 57 (26.1%) of the recommendations, safety depended on the severity of liver cirrhosis and was 'unknown' in 39 (17.9%) recommendations. Large alterations in pharmacodynamics were the main reason for classifying a drug as 'unsafe'. For 67 drugs (31%), a dose adjustment was needed.

Conclusions: Over 200 recommendations were developed for the safe use of drugs in patients with liver cirrhosis. Implementing these recommendations into clinical practice can possibly enhance medication safety in this vulnerable patient group.

PubMed Disclaimer

Conflict of interest statement

Funding

This work was supported by ZonMw GGG-STIP Grant number 836044009. ZonMw is the Dutch national organisation for health research and healthcare innovation.

Conflict of interest

Rianne A. Weersink, Margriet Bouma, David M. Burger, Joost P.H. Drenth, S. Froukje Harkes-Idzinga, Nicole G.M. Hunfeld, Herold J. Metselaar, Margje H. Monster-Simons, Katja Taxis and Sander D. Borgsteede have no conflicts of interest directly relevant to the content of this article.

Figures

Fig. 1
Fig. 1
Overview of evidence-based recommendations. Results are expressed as a percentage of the total number of recommendations
See this image and copyright information in PMC

References

    1. Thomsen LA, Winterstein AG, Søndergaard B, Haugbølle LS, Melander A. Systematic review of the incidence and characteristics of preventable adverse drug events in ambulatory care. Ann Pharmacother. 2007;41(9):1411–1426. doi: 10.1345/aph.1H658. - DOI - PubMed
    1. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ. 2004;329(7456):15–19. doi: 10.1136/bmj.329.7456.15. - DOI - PMC - PubMed
    1. Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64(12):1147–1161. doi: 10.1007/s00228-008-0553-z. - DOI - PubMed
    1. Delco F, Tchambaz L, Schlienger R, Drewe J, Krahenbuhl S. Dose adjustment in patients with liver disease. Drug Saf. 2005;28(6):529–545. doi: 10.2165/00002018-200528060-00005. - DOI - PubMed
    1. Westphal J, Brogard J. Drug administration in chronic liver disease. Drug Saf. 1997;17(1):47–73. doi: 10.2165/00002018-199717010-00004. - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources